JP5732058B2 - 眼科用水性注射可能組成物およびその使用方法 - Google Patents

眼科用水性注射可能組成物およびその使用方法 Download PDF

Info

Publication number
JP5732058B2
JP5732058B2 JP2012530970A JP2012530970A JP5732058B2 JP 5732058 B2 JP5732058 B2 JP 5732058B2 JP 2012530970 A JP2012530970 A JP 2012530970A JP 2012530970 A JP2012530970 A JP 2012530970A JP 5732058 B2 JP5732058 B2 JP 5732058B2
Authority
JP
Japan
Prior art keywords
composition
therapeutic agent
highly viscous
viscous mass
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012530970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505934A5 (pt
JP2013505934A (ja
Inventor
マスード エー． チョウハン，
マスード エー． チョウハン，
トーマス シー． ホーマン，
トーマス シー． ホーマン，
アーネスト ジェイ． カスティロ，
アーネスト ジェイ． カスティロ，
ウェズレー ウェーシン ハン，
ウェズレー ウェーシン ハン，
Original Assignee
アルコン リサーチ， リミテッド
アルコン リサーチ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン リサーチ， リミテッド, アルコン リサーチ， リミテッド filed Critical アルコン リサーチ， リミテッド
Publication of JP2013505934A publication Critical patent/JP2013505934A/ja
Publication of JP2013505934A5 publication Critical patent/JP2013505934A5/ja
Application granted granted Critical
Publication of JP5732058B2 publication Critical patent/JP5732058B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012530970A 2009-09-23 2010-09-21 眼科用水性注射可能組成物およびその使用方法 Expired - Fee Related JP5732058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24491609P 2009-09-23 2009-09-23
US61/244,916 2009-09-23
PCT/US2010/049623 WO2011037908A1 (en) 2009-09-23 2010-09-21 Injectable aqueous ophthalmic composition and method of use therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015082366A Division JP2015129194A (ja) 2009-09-23 2015-04-14 眼科用水性注射可能組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2013505934A JP2013505934A (ja) 2013-02-21
JP2013505934A5 JP2013505934A5 (pt) 2013-10-10
JP5732058B2 true JP5732058B2 (ja) 2015-06-10

Family

ID=43034434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530970A Expired - Fee Related JP5732058B2 (ja) 2009-09-23 2010-09-21 眼科用水性注射可能組成物およびその使用方法
JP2015082366A Withdrawn JP2015129194A (ja) 2009-09-23 2015-04-14 眼科用水性注射可能組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015082366A Withdrawn JP2015129194A (ja) 2009-09-23 2015-04-14 眼科用水性注射可能組成物およびその使用方法

Country Status (15)

Country Link
US (3) US20110071091A1 (pt)
EP (1) EP2480205B1 (pt)
JP (2) JP5732058B2 (pt)
KR (2) KR20120069741A (pt)
CN (1) CN102695497B (pt)
AR (1) AR078293A1 (pt)
AU (1) AU2010298480B2 (pt)
BR (1) BR112012006642A2 (pt)
CA (1) CA2772795A1 (pt)
ES (1) ES2568462T3 (pt)
MX (1) MX2012003196A (pt)
PL (1) PL2480205T3 (pt)
TW (1) TWI492769B (pt)
WO (1) WO2011037908A1 (pt)
ZA (1) ZA201201438B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
US20140178327A1 (en) 2012-12-21 2014-06-26 Coopervision International Holding Company, Lp Antimicrobial Ophthalmic Devices
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
US20160279055A1 (en) * 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20170119885A1 (en) * 2014-04-28 2017-05-04 Hampton Technologies Ophthalmic compositions and methods for treating eyes
US20150366311A1 (en) 2014-06-19 2015-12-24 Coopervision International Holding Company, Lp Protection of Contact Lenses from Microbial Contamination Caused by Handling
EP3302061A4 (en) * 2015-06-05 2019-02-27 Kato Pharmaceuticals, Inc. EXTENDED RELEASE COMPOSITIONS
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017196881A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
JP7057290B2 (ja) 2016-06-27 2022-04-19 アキリオン ファーマシューティカルズ，インコーポレーテッド 医学的障害を治療するためのキナゾリン及びインドール化合物
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
WO2020118045A1 (en) * 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
KR101352666B1 (ko) 2004-09-24 2014-02-14 허큘레스 인코포레이티드 피부관리 제품용 높은 ｄｓ 양이온성 폴리갈락토만난
KR20070104931A (ko) * 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
CN100433805C (zh) * 2005-06-29 2008-11-12 上海广电（集团）有限公司中央研究院 一种数字电视接收机及其信号传递方法
AU2006302212B2 (en) * 2005-10-08 2012-12-20 Apellis Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
MX2010003630A (es) * 2007-10-02 2010-04-21 Potentia Pharmaceuticals Inc Administracion sostenida de analogos de compstatina desde geles.
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
US8530189B2 (en) 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
AU2011248129B2 (en) * 2010-05-05 2014-10-09 Alcon Inc. Stabilized ophthalmic galactomannan formulations

Also Published As

Publication number Publication date
EP2480205B1 (en) 2016-03-16
TW201111003A (en) 2011-04-01
CN102695497B (zh) 2016-01-06
AU2010298480A1 (en) 2012-03-29
AU2010298480B2 (en) 2014-08-07
JP2015129194A (ja) 2015-07-16
MX2012003196A (es) 2012-04-30
CN102695497A (zh) 2012-09-26
JP2013505934A (ja) 2013-02-21
ZA201201438B (en) 2013-05-29
US9446093B2 (en) 2016-09-20
ES2568462T3 (es) 2016-04-29
US20140094419A1 (en) 2014-04-03
PL2480205T3 (pl) 2016-09-30
BR112012006642A2 (pt) 2016-05-03
KR20170008895A (ko) 2017-01-24
EP2480205A1 (en) 2012-08-01
WO2011037908A1 (en) 2011-03-31
US20110071091A1 (en) 2011-03-24
TWI492769B (zh) 2015-07-21
US20160361254A1 (en) 2016-12-15
CA2772795A1 (en) 2011-03-31
AR078293A1 (es) 2011-10-26
KR20120069741A (ko) 2012-06-28

Similar Documents

Publication Publication Date Title
JP5732058B2 (ja) 眼科用水性注射可能組成物およびその使用方法
KR101555293B1 (ko) 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액
TWI362264B (en) Composition and use for treating a posterior segment of an eye
CN101484177B (zh) 含有藻酸或其盐的眼科用组合物
JPH11510497A (ja) Ｏ−カルボキシアルキルキトサンを含む配合物及び眼科領域での使用方法
TW200400055A (en) Ophthalmic formulation with novel gum composition
AU2010326099B2 (en) Carboxyvinyl polymer-container nanoparticle suspensions
SA516380321B1 (ar) مستحضرات للعين لتوصيل الدواء إلى الجزء الخلفي من العين
US20040266725A1 (en) Polysaccharide-containing compositions and use thereof
JP2001501194A (ja) ゲル形成性医薬組成物
US20100317615A1 (en) Method of enhancing ocular penetration of a drug in an eyedrop
WO2022065404A1 (ja) 耳内投与用の医薬組成物
JP2017537981A (ja) リン酸カルシウムナノ粒子封入医薬用半固体ゲル
WO2017151651A1 (en) Pharmaceutical in situ gelling compositions
MXPA06005146A (en) Compositions and methods for treating a posterior segment of an eye

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140523

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150410

R150 Certificate of patent or registration of utility model

Ref document number: 5732058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees